Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment ◽

Open Issues

Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.11.19 ◽

2019 ◽

Vol 8 (6) ◽

pp. 1086-1090

Author(s):

Yusuke Chihara ◽

Tadaaki Yamada ◽

Junji Uchino ◽

Nobuyo Tamiya ◽

Yoshiko Kaneko ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(11)72435-2 ◽

2011 ◽

Vol 47 ◽

pp. S630

Author(s):

K. Asami ◽

T. Koizumi ◽

K. Hirai ◽

S. Ameshima ◽

A. Tsukadaira ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Journal of Clinical Oncology ◽

10.1200/jco.2016.70.2472 ◽

2017 ◽

Vol 35 (6) ◽

pp. 692-692 ◽

Cited By ~ 3

Author(s):

Young Hak Kim

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

European Journal of Cancer Supplements ◽

10.1016/j.ejcsup.2011.02.004 ◽

2011 ◽

Vol 9 (1) ◽

pp. 2 ◽

Cited By ~ 1

Author(s):

G. de Lima Lopes ◽

J. Segel ◽

D. Tan ◽

Y. Do ◽

T. Mok ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

Lung Cancer ◽

10.1016/j.lungcan.2010.12.008 ◽

2011 ◽

Vol 71 (3) ◽

pp. 249-257 ◽

Cited By ~ 63

Author(s):

C. Gridelli ◽

F. De Marinis ◽

M. Di Maio ◽

D. Cortinovis ◽

F. Cappuzzo ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden

Journal of Medical Economics ◽

10.1080/13696998.2021.1901722 ◽

2021 ◽

pp. 1-1

Author(s):

Fredrik O.L. Nilsson ◽

Peter Gal ◽

Ivan Houisse ◽

Jasmina I Ivanova ◽

Sandra T Asanin

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

The Cost ◽

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd010383.pub2 ◽

2016 ◽

Cited By ~ 40

Author(s):

Janette Greenhalgh ◽

Kerry Dwan ◽

Angela Boland ◽

Victoria Bates ◽

Fabio Vecchio ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations

Translational Lung Cancer Research ◽

10.21037/tlcr.2018.03.08 ◽

2018 ◽

Vol 7 (S2) ◽

pp. S134-S137 ◽

Cited By ~ 1

Author(s):

Lore Decoster ◽

Philippe Giron ◽

Sacha Mignon ◽

Jacques De Grève

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd010383.pub3 ◽

2021 ◽

Author(s):

Janette Greenhalgh ◽

Angela Boland ◽

Victoria Bates ◽

Fabio Vecchio ◽

Yenal Dundar ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study

Medical Oncology ◽

10.1007/s12032-012-0450-2 ◽

2013 ◽

Vol 30 (1) ◽

Cited By ~ 18

Author(s):

Kazunari Tateishi ◽

Takashi Ichiyama ◽

Kazuya Hirai ◽

Toshihiko Agatsuma ◽

Shigeru Koyama ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Research ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽